Leading global genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter, which delivers expert genomics sequencing solutions to healthcare businesses, as well as academic and government institutions worldwide (GS).
“The genomic services business of Beckman Coulter is an ideal fit with GENEWIZ’s global strategy and expansion plans,” said Dr. Steve Sun, GENEWIZ Chairman and CEO. “Our two companies share a common mission and vision, to offer scientists around the world consistently-reliable genomics service solutions that will advance innovations and scientific discoveries.”
The synergies of this acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25+ years of genomics expertise and capabilities. GS’s comprehensive Sanger Sequencing, Next Generation Sequencing, Bioinformatics, and CLIA/Clinical services will complement GENEWIZ’s existing genomics services. With an international presence in the U.S. and a Pan-European presence centered in the UK, GS presents an immediate opportunity to strengthen GENEWIZ’s global access and value to customers through a stronger network of global labs and office locations in the U.S., UK, China, and Japan.
“GS’s proven leadership and experienced team of industry experts have built an efficient workflow that allows for the delivery of quality and timely results to its customers,” continued Dr. Sun. “The integration of these two businesses will allow for an increased level of service and value to customers worldwide. We look forward to working with the talented GS team to best serve our customers, and be an instrumental part of the future growth of GENEWIZ.”
GS and GENEWIZ will collaboratively align to ensure there is a seamless transition for both organizations and its customer base. The agreement has been approved by the boards of directors of both companies and closed effective immediately.
Source: GENEWIZ
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
